Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer.

ABSTRACT:

Introduction

Metastatic prostate cancer is a heterogeneous disease characterized by clinical and genomic heterogeneity. Many prostate cancers harbor mutations causing DNA repair deficiency, specifically homologous recombination deficiency, sensitizing to drugs that inhibit poly ADP-ribose polymerase (PARP). PARP is an enzyme that is involved in single-stranded DNA repair and is the target of newly approved treatments for metastatic prostate cancer.

Areas covered

Here, the authors' review the clinical trials leading to the recent approvals of two PARP inhibitors (PARPi), olaparib and rucaparib, specifically TOPARP-A, TOPARP-B, PROfound and TRITON-2. They also compare the different FDA approvals for both of these medications and outline the safety of this class of drugs in pro

SUBMITTER: Maughan BL 

PROVIDER: S-EPMC8419006 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature